Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by reducing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion. This insulin-independent mechanism helps lower fasting and postprandial blood glucose levels. Empagliflozin also contributes to modest weight reduction and blood pressure lowering, and has demonstrated cardiovascular and renal protective benefits in patients with type 2 diabetes.

Linagliptin (5 mg)
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones such as GLP-1 and GIP. These hormones stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. As a result, Linagliptin improves glycemic control without significantly increasing the risk of hypoglycemia. It is primarily excreted via the biliary route, making it suitable for patients with renal impairment.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Empalina Tablet is indicated for:

• Management of type 2 diabetes mellitus in adults

• Patients inadequately controlled on monotherapy with either empagliflozin or linagliptin

• Adjunct therapy to diet and exercise to improve glycemic control

• Patients requiring combination therapy for better blood glucose regulation

Key Benefits

• Dual mechanism for effective and sustained glycemic control

• Low risk of hypoglycemia when used without insulin or sulfonylureas

• Supports weight neutrality or modest weight loss

• Provides cardiovascular and renal protective benefits

• Convenient once-daily dosing improves treatment adherence

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

The usual recommended dose is one tablet once daily, taken orally with or without food, or as directed by a healthcare professional. Dosage should be individualized based on patient response, renal function, and overall treatment goals. Regular monitoring of blood glucose levels is advised during therapy.

Precautions and Warnings

• Not indicated for use in type 1 diabetes mellitus or diabetic ketoacidosis

• Use with caution in patients with severe renal impairment

• Adequate hydration should be maintained to reduce the risk of volume depletion

• Monitor for signs of urinary tract or genital infections during therapy

• Use during pregnancy and breastfeeding only if prescribed by a physician

Possible Side Effects

Common side effects may include increased urination, urinary tract infections, genital infections, nasopharyngitis, or headache. Hypoglycemia is uncommon unless used in combination with insulin or insulin secretagogues. Most side effects are mild to moderate and manageable with appropriate medical guidance.

Storage

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.